BridgeBio Pharma, Inc.
BBIO
$68.55
$2.603.94%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -164.04M | -192.86M | -182.74M | -181.90M | -167.42M |
| Total Depreciation and Amortization | 1.19M | 1.44M | 1.40M | 1.32M | 1.28M |
| Total Amortization of Deferred Charges | 1.82M | 1.45M | 4.52M | -- | 1.62M |
| Total Other Non-Cash Items | 88.50M | 83.95M | 71.19M | 80.48M | 81.45M |
| Change in Net Operating Assets | -124.74M | 49.61M | -3.93M | 19.42M | -116.17M |
| Cash from Operations | -197.28M | -56.42M | -109.57M | -80.68M | -199.24M |
| Capital Expenditure | -69.00K | -33.00K | -470.00K | -594.00K | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -42.67M | -14.32M | 4.93M | -12.41M | -1.60M |
| Cash from Investing | -42.74M | -14.35M | 4.46M | -13.00M | -1.60M |
| Total Debt Issued | 632.50M | 0.00 | 0.00 | 300.00M | 575.00M |
| Total Debt Repaid | -- | 0.00 | 0.00 | 0.00 | -459.00M |
| Issuance of Common Stock | 28.06M | 13.21M | 8.02M | 7.16M | 5.76M |
| Repurchase of Common Stock | -86.57M | -7.43M | -3.03M | -2.00M | -50.05M |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -24.09M | -7.96M | -5.89M | -3.12M | -11.38M |
| Cash from Financing | 549.89M | -2.18M | -894.00K | 302.04M | 60.33M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 309.88M | -72.96M | -106.00M | 208.36M | -140.50M |